RS63285B1 - L-valinat hidroksipropil tiazolidin karboksamidnog derivata, njegova so i njegov kristalni oblik - Google Patents
L-valinat hidroksipropil tiazolidin karboksamidnog derivata, njegova so i njegov kristalni oblikInfo
- Publication number
- RS63285B1 RS63285B1 RS20220547A RSP20220547A RS63285B1 RS 63285 B1 RS63285 B1 RS 63285B1 RS 20220547 A RS20220547 A RS 20220547A RS P20220547 A RSP20220547 A RS P20220547A RS 63285 B1 RS63285 B1 RS 63285B1
- Authority
- RS
- Serbia
- Prior art keywords
- valinate
- salt
- crystal form
- carboxamide derivative
- hydroxypropylthiazolidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662274674P | 2016-01-04 | 2016-01-04 | |
| US14/987,586 US9447055B1 (en) | 2016-01-04 | 2016-01-04 | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| US201662395664P | 2016-09-16 | 2016-09-16 | |
| US201662407918P | 2016-10-13 | 2016-10-13 | |
| PCT/EP2017/050101 WO2017118641A1 (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| EP17700392.8A EP3400217B1 (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative, its salt and crystal form thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63285B1 true RS63285B1 (sr) | 2022-06-30 |
Family
ID=57799697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220548A RS63286B1 (sr) | 2016-01-04 | 2017-01-04 | Istovremeno davanje alfa-amino estra hidroksipropiltiazolidin karboksamidnog derivata i tokolitičkog agensa |
| RS20220547A RS63285B1 (sr) | 2016-01-04 | 2017-01-04 | L-valinat hidroksipropil tiazolidin karboksamidnog derivata, njegova so i njegov kristalni oblik |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220548A RS63286B1 (sr) | 2016-01-04 | 2017-01-04 | Istovremeno davanje alfa-amino estra hidroksipropiltiazolidin karboksamidnog derivata i tokolitičkog agensa |
Country Status (23)
| Country | Link |
|---|---|
| EP (4) | EP4140988A1 (sr) |
| JP (5) | JP7169573B2 (sr) |
| KR (2) | KR20180099708A (sr) |
| CN (1) | CN108779087A (sr) |
| AU (4) | AU2017205670B2 (sr) |
| CA (2) | CA3009576A1 (sr) |
| DK (2) | DK3397622T3 (sr) |
| EA (1) | EA036990B1 (sr) |
| ES (2) | ES2915948T3 (sr) |
| HR (2) | HRP20220673T1 (sr) |
| HU (2) | HUE058871T2 (sr) |
| IL (4) | IL284912B (sr) |
| LT (2) | LT3400217T (sr) |
| MA (2) | MA43580A (sr) |
| MX (3) | MX2018008157A (sr) |
| PL (2) | PL3397622T3 (sr) |
| PT (2) | PT3400217T (sr) |
| RS (2) | RS63286B1 (sr) |
| SG (4) | SG11201804594YA (sr) |
| SI (2) | SI3397622T1 (sr) |
| UA (2) | UA125377C2 (sr) |
| WO (2) | WO2017118639A1 (sr) |
| ZA (1) | ZA201903769B (sr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3009576A1 (en) * | 2016-01-04 | 2017-07-13 | Merck Serono S.A. | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| RU2711615C1 (ru) * | 2019-09-12 | 2020-01-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения эндометриоза на основании экспериментальной модели у крыс |
| EP4034129A4 (en) * | 2019-09-23 | 2023-11-01 | The Board of Trustees of the Leland Stanford Junior University | TREATMENT PROCEDURES FOR GESTATIONAL EXTENSION AND FOR MENSTRUAL OR GESTATIONAL COMPLICATIONS |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835175A (en) | 1971-03-15 | 1974-09-10 | Research Corp | 9-fluorenylmethanol haloformates, carbonates and thiocarbonates |
| US3839396A (en) | 1971-07-15 | 1974-10-01 | Shionogi & Co | 9-lower alkyl-9-fluorenyl carbonates |
| US4108846A (en) | 1977-02-01 | 1978-08-22 | Hoffmann-La Roche Inc. | Solid phase synthesis with base N alpha-protecting group cleavage |
| SE430885B (sv) | 1980-03-24 | 1983-12-19 | Ferring Ab | Oxytocin-derivat |
| US4581167A (en) | 1982-01-19 | 1986-04-08 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| US4508657A (en) | 1982-01-19 | 1985-04-02 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| EP0112809B1 (en) | 1982-12-21 | 1986-05-28 | Ferring AB | Vasotocin derivatives |
| US4460501A (en) | 1983-08-30 | 1984-07-17 | Research Corporation | Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides |
| US5370135A (en) * | 1993-10-13 | 1994-12-06 | Biex, Inc. | Use of estriol measurement to monitor tocolytic therapy |
| DE4434488A1 (de) * | 1994-09-14 | 1996-03-21 | Schering Ag | Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| IN188411B (sr) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| CA2410655A1 (en) * | 2000-05-30 | 2001-12-06 | John H. Dodd | Dihydropyridine compounds for the inhibition of calcium-influx |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| ES2277640T3 (es) | 2002-02-27 | 2007-07-16 | Ferring Bv | Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina. |
| BR0308748A (pt) * | 2002-03-28 | 2005-01-11 | Applied Research Systems | Derivados de tiazolidina carboxamida como moduladores do receptor f de prostaglandina e método de preparação de um derivado de tiazolidina carboxamida |
| GB0208785D0 (en) * | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
| US7521530B2 (en) * | 2002-06-11 | 2009-04-21 | Universite De Montreal | Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| CA2509687C (en) * | 2002-12-12 | 2012-08-14 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| EP2493874A1 (en) | 2009-10-30 | 2012-09-05 | Glaxo Group Limited | Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl]-6- [(1s) - 1 -methylpropyl]-2,5- piperazinedione |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| AU2014397706A1 (en) * | 2014-06-16 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Retosiban for the treatment of pre-term labour |
| CN106795110A (zh) | 2014-07-02 | 2017-05-31 | 奥布赛瓦股份公司 | 治疗ot‑r活性相关的病症的方法中可用的晶体(3z，5s)‑5‑(羟甲基)‑1‑[(2’‑甲基‑1，1’‑联苯‑4‑基)羰基]吡咯烷‑3‑酮o‑甲基肟 |
| EP3037101B1 (en) | 2014-12-22 | 2019-03-06 | Ferring B.V. | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
| US9447055B1 (en) * | 2016-01-04 | 2016-09-20 | Merck Serono S.A. | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| CA3009576A1 (en) * | 2016-01-04 | 2017-07-13 | Merck Serono S.A. | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
-
2017
- 2017-01-04 CA CA3009576A patent/CA3009576A1/en active Pending
- 2017-01-04 CN CN201780015011.9A patent/CN108779087A/zh active Pending
- 2017-01-04 ES ES17700391T patent/ES2915948T3/es active Active
- 2017-01-04 KR KR1020187018929A patent/KR20180099708A/ko not_active Application Discontinuation
- 2017-01-04 HU HUE17700392A patent/HUE058871T2/hu unknown
- 2017-01-04 AU AU2017205670A patent/AU2017205670B2/en active Active
- 2017-01-04 EP EP22152238.6A patent/EP4140988A1/en active Pending
- 2017-01-04 PT PT177003928T patent/PT3400217T/pt unknown
- 2017-01-04 MA MA043580A patent/MA43580A/fr unknown
- 2017-01-04 SG SG11201804594YA patent/SG11201804594YA/en unknown
- 2017-01-04 MX MX2018008157A patent/MX2018008157A/es unknown
- 2017-01-04 PL PL17700391T patent/PL3397622T3/pl unknown
- 2017-01-04 UA UAA201806074A patent/UA125377C2/uk unknown
- 2017-01-04 SI SI201731162T patent/SI3397622T1/sl unknown
- 2017-01-04 SG SG11201804789QA patent/SG11201804789QA/en unknown
- 2017-01-04 IL IL284912A patent/IL284912B/en unknown
- 2017-01-04 MX MX2018008304A patent/MX2018008304A/es unknown
- 2017-01-04 SG SG10202009769WA patent/SG10202009769WA/en unknown
- 2017-01-04 RS RS20220548A patent/RS63286B1/sr unknown
- 2017-01-04 SI SI201731161T patent/SI3400217T1/sl unknown
- 2017-01-04 EP EP22153566.9A patent/EP4144351A1/en active Pending
- 2017-01-04 ES ES17700392T patent/ES2916835T3/es active Active
- 2017-01-04 PT PT177003910T patent/PT3397622T/pt unknown
- 2017-01-04 WO PCT/EP2017/050099 patent/WO2017118639A1/en active Application Filing
- 2017-01-04 JP JP2018529284A patent/JP7169573B2/ja active Active
- 2017-01-04 DK DK17700391.0T patent/DK3397622T3/da active
- 2017-01-04 UA UAA201806830A patent/UA125118C2/uk unknown
- 2017-01-04 WO PCT/EP2017/050101 patent/WO2017118641A1/en active Application Filing
- 2017-01-04 HR HRP20220673TT patent/HRP20220673T1/hr unknown
- 2017-01-04 EP EP17700392.8A patent/EP3400217B1/en active Active
- 2017-01-04 HR HRP20220674TT patent/HRP20220674T1/hr unknown
- 2017-01-04 CA CA3009573A patent/CA3009573A1/en active Pending
- 2017-01-04 LT LTEPPCT/EP2017/050101T patent/LT3400217T/lt unknown
- 2017-01-04 DK DK17700392.8T patent/DK3400217T3/da active
- 2017-01-04 AU AU2017205254A patent/AU2017205254B2/en active Active
- 2017-01-04 EP EP17700391.0A patent/EP3397622B1/en active Active
- 2017-01-04 SG SG10202009723PA patent/SG10202009723PA/en unknown
- 2017-01-04 HU HUE17700391A patent/HUE058872T2/hu unknown
- 2017-01-04 PL PL17700392T patent/PL3400217T3/pl unknown
- 2017-01-04 RS RS20220547A patent/RS63285B1/sr unknown
- 2017-01-04 EA EA201891095A patent/EA036990B1/ru unknown
- 2017-01-04 JP JP2018529634A patent/JP6933322B2/ja active Active
- 2017-01-04 KR KR1020187018312A patent/KR20180100120A/ko not_active Application Discontinuation
- 2017-01-04 MA MA043549A patent/MA43549A/fr unknown
- 2017-01-04 LT LTEPPCT/EP2017/050099T patent/LT3397622T/lt unknown
-
2018
- 2018-05-31 IL IL259742A patent/IL259742B/en unknown
- 2018-06-26 IL IL260286A patent/IL260286B/en unknown
- 2018-06-29 MX MX2022000154A patent/MX2022000154A/es unknown
-
2019
- 2019-05-24 ZA ZA2019/03769A patent/ZA201903769B/en unknown
-
2021
- 2021-08-05 JP JP2021129297A patent/JP7432284B2/ja active Active
- 2021-08-16 AU AU2021218009A patent/AU2021218009B2/en active Active
- 2021-12-22 IL IL289256A patent/IL289256A/en unknown
-
2022
- 2022-10-18 JP JP2022166814A patent/JP7377588B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233151A patent/AU2023233151A1/en active Pending
- 2023-10-25 JP JP2023183345A patent/JP2024012376A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245774A1 (zh) | Copanlisib及其二鹽酸鹽的合成 | |
| HRP20190527T1 (hr) | Sinteza kopanlisiba i njegove dihidrokloridne soli | |
| IL250290B (en) | A salt of a monocyclic pyridine derivative and its crystalline form | |
| SG11201507897SA (en) | Salt of pyrazoloquinoline derivative, and crystal thereof | |
| IL284912A (en) | -Valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystalline polymorph thereof | |
| ZA201607658B (en) | Carboxamide derivatives | |
| AP2016009554A0 (en) | Carboxamide derivatives | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| EP3505516A4 (en) | QUINAZOLINE DERIVATIVE SALT CRYSTAL | |
| AU2021218003B2 (en) | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | |
| HK1251560A1 (zh) | 噻二唑衍生物類dpp-iv抑制劑的結晶及其用途 | |
| IL248801A0 (en) | Carboxamide history |